LFG
EBS icon

Larson Financial Group’s Emergent Biosolutions EBS Stock Holding History

Larson Financial Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763 Buy
91
+12
+15% +$100 ﹤0.01% 3395
2026
Q1 		$656 Buy
+79
New +$818 ﹤0.01% 3263

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Larson Financial Group's EBS Position: Q2 2026 in Review

Larson Financial Group increased its Emergent Biosolutions (EBS) stake by 15% in Q2 2026, buying an estimated $100 and bringing the position to 91 shares worth $763. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Larson Financial Group first reported a position in EBS in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Larson Financial Group held 91 shares of Emergent Biosolutions worth $763 as of Q2 2026.
  • Larson Financial Group bought 12 Emergent Biosolutions shares in Q2 2026, an estimated $100.
  • Emergent Biosolutions made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3395 holding.
  • Larson Financial Group first reported a position in Emergent Biosolutions in Q1 2026 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.